title: Vagus nerve stimulation for refractory epilepsy.
abstract: Vagus nerve stimulation (VNS) is a neurophysiological treatment for patients with medically or surgically refractory epilepsy. Since the first human implant in 1989, more than 10 000 patients have been treated with VNS. Two randomized controlled studies have shown a statistically significant decrease in seizure frequency during a 12-week treatment period versus a baseline period when 'high stimulation' mode was compared with 'low stimulation' mode. The efficacy appears to increase over time. In general, one third of the patients show a >50% reduction of seizure frequency; one third show a 30-50% seizure reduction, and one third of patients show no response. Few patients become seizure-free. Side effects during stimulation are mainly voice alteration, coughing, throat paraesthesia and discomfort. When studied on a long-term basis, VNS is an efficacious, safe and cost-effective treatment not only in adults but also in children and the elderly. The precise mechanism of action remains to be elucidated. In recent years much progress has been made through neurophysiological, neuroanatomical, neurochemical and cerebral blood flow studies in animals and patients treated with VNS. Further elucidation of the mechanism of action of VNS may increase its clinical efficacy and our general understanding of some physiopathological aspects of epilepsy. Finally, VNS may become an alternative treatment for other conditions such as depression and pain.
authors.affiliation: Reference Centre for Refractory Epilepsy, Department of Neurology, Ghent University Hospital, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Boon
authors.forename: K
authors.initials: K
authors.lastname: Vonck
authors.forename: J
authors.initials: J
authors.lastname: De Reuck
authors.forename: J
authors.initials: J
authors.lastname: Caemaert
mesh_terms: D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation / Q000379:methods*; D004827:Epilepsy / Q000628:therapy*; D006801:Humans; D014630:Vagus Nerve